Lymphatic malformations (LMs) show phenotypic variability, as well as clinical and genetic heterogeneity. Inheritance is autosomal dominant, recessive or X-linked and major genes involved in predisposition for LMs are continuously being discovered. The literature also indicates that somatic mutations play an important role in the development of LMs. In fact, activating somatic mutations in PIK3CA have been reported in lymphatic endothelial cells obtained from patients with different kinds of LM. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, couple risk assessment and access to clinical trials.
General information about the disease
The term "lymphatic malformations" refers to a broad range of lymphatic system defects (aplasia, hypoplasia and hyperplasia of lymphatic channels and nodes (1) , or localized unifocal lesions consisting of dilated lymphatic channels filled with lymph but disconnected from the rest of the lymphatic system (2) ). In many cases these defects cause lymphedema (abnormal accumulation of interstitial fluid due to inefficient uptake and reduced lymphatic flow); in other cases lymphatic malformations are not associated with lymphedema. In the past, lymphatic malformations (LMs) and primary lymphedema were considered two different entities, however according to the Hamburg classification, primary lymphedema is a clinical manifestation of LMs appearing in later stages of lymphangiogenesis (truncular LMs) (1), whereas extratruncular lesions, known as cystic/ cavernous lymphangiomas, develop during earlier stages of lymphangiogenesis (1) . The prevalence of truncular and extratruncular LMs is 1-5/10,000.
In the first step of diagnosis, clinical history and physical examination (3) of patients with LMs should reveal whether the malformation is truncular, extratruncular or syndromic, and if the disorder is inherited or sporadic (4) . Lymphoscintigraphy has proved extremely useful for depicting specific lymphatic abnormalities (3) . Radioactive colloid is injected into the toe web spaces and uptake by the ilioinguinal nodes is measured at intervals. Lymphoscintigraphy is performed to determine if there is a lack of uptake of radioactive tracer. Other diagnostic tools used to elucidate lymphangiodysplasia/lymphedema syndromes (also in newborns and children) include lymphangioscintigraphy, magnetic resonance imaging (MR lymphography and MR angiography), computed tomography (CT), CT lymphograms, 3-D oil contrast lymphography, CT-SPECT, ultrasonography, indirect lymphography, near infrared fluorescent imaging (also known as ICG lymphography) and fluorescent microlymphangiography (3). Lymphoscintigraphy is not always essential for diagnosis and one can proceed directly to molecular testing (5) .
Differential diagnosis should include hereditary lymphedema; lymphedema-distichiasis; Emberger syndrome; hypotrichosis-lymphedema-telangiectasia syndrome; microcephaly with or without chorioretinopathy, lymphedema and mental retardation; lymphedema-choanal atresia; Hennekam lymphangiectasia-lymphedema syndrome; anhidrotic ectodermal dysplasia with immunodeficiency, osteopetrosis and lymphedema; congenital lipomatous overgrowth, vascular malformations and epidermal nevi syndrome; and Klippel-Trenaunay syndrome.
LMs are associated with several conditions characterized by allelic and locus heterogeneity and different modes of inheritance. Inheritance can be autosomal dominant, autosomal recessive or X-linked recessive. Genes involved in a predisposition to lymphedema triggered by surgery have also been reported (6, 7) . 
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Aims of the test
• To determine the gene defect responsible for the disease;
• To confirm clinical diagnosis;
• To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.
Test characteristics Specialist centers/Published guidelines
The test is listed in the Orphanet database and is offered by 22 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 7 accredited medical genetic laboratories in the US. Guidelines for clinical use of the test are described in disease-specific chapters of Genetics Home Reference (ghr.nlm. nih.gov) and Gene Reviews (36) .
Test strategy
Clinically distinguishable syndromes can be analyzed by sequencing only those genes known to be associated with that specific disease using Sanger or Next Generation Sequencing (NGS); if the results are negative, or more generally if clinical signs are ambiguous for diagnosis, a multi-gene NGS panel is used to detect nucleotide variations in coding exons and flanking introns of the above genes.
• If the disorder is familial, the test is performed to identify pathogenic germline variants.
• If the disease is sporadic, the first step is to identify germline variants and check the possibility of a dominant de novo mutation. • If the test is negative or if only a single germline variant in a paradominant gene (RASA1 or ITGA9) is found, the second step is to analyze affected tissues to find de novo somatic mutations that could be present only at the site of the malformation.
The test for paradominant (RASA1 or ITGA9) and de novo (AKT1 and PIK3CA) somatic variations is to compare results obtained from germinal lineage (blood or saliva specimens) and affected tissue. For variant selection, a cut-off value (related to biopsy and blood results) is used, and if the variant frequency is higher than the cut-off value it is considered for further analysis. The cut-off depends on tissue quality, extraction method, biocomputing software and other parameters. Potentially causative variants need to be verified by further means (e.g. cloning + Sanger sequencing, Sanger sequencing, minisequencing).
Genetic analysis should be extended to relatives when the test is positive in familial cases or when a de novo germline variant is found that could be inherited by offspring. Potentially causative variants and regions with low coverage are Sanger-sequenced. Sanger sequencing is also used for family segregation studies.
Multiplex Ligation Probe Amplification (MLPA) is used to detect duplications and deletions in FOXC2, GATA2, NRAS, HRAS and BRAF.
To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K 3 EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.
A frozen intra-lesional biopsy specimen, in addition to blood or saliva, is necessary to test for somatic variations.
Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results
Positive
Identification of pathogenic variants in the above genes confirms the clinical diagnosis and is an indication for family studies.
A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures. Inconclusive Detection of a variant of unknown or uncertain significance (VUS): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the following possibilities:
• Alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments. • Sequence variations in genomic regions not investigated by the test, such as regulatory regions, 5'-and 3'-UTR) and deep intronic regions. • Variations in other genes not investigated by the present test.
Unexpected
Unexpected results may emerge from the test, for example information regarding consanguinity, absence of family correlation or other genetically-based diseases.
Risk for progeny
If the identified pathogenic variant has autosomal dominant transmission, the probability that an affected carrier transmit the disease variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived.
In autosomal recessive mutations, both parents are usually healthy carriers. In this case, the probability of transmitting the disorder to the offspring is 25% in any pregnancy of the couple, irrespective of the sex of the child. An affected individual generates healthy carrier sons and daughters in all cases, except in pregnancies with a healthy carrier partner. In these cases, the risk of an affected son or daughter is 50%.
In X-linked recessive inheritance, affected males transmit the pathogenic variant to their daughters and the probability that a female carrier transmit the pathogenic variant to her offspring is 50% in any pregnancy irrespective of the sex of the child conceived. Females who inherit the pathogenic variant are carriers and usually unaffected. Males who inherit the pathogenic variant are affected.
De novo somatic variations cannot be inherited or transmitted. In paradominant inheritance, only the germline genetic variant is transmitted in an autosomal dominant fashion and the probability that carriers transmit the germline pathogenic variant to their children is 50% in any pregnancy, irrespective of the sex of the child conceived.
Limits of the test
The test is limited by current scientific knowledge regarding the genes and diseases.
Analytical sensitivity (proportion of positive tests when the genotype is truly present) and specificity (proportion of negative tests when the genotype is not present) NGS Analytical sensitivity >99.99%, with a minimum coverage of 10X; Analytical specificity 99.99%. SANGER Analytical sensitivity >99.99%; Analytical specificity 99.99%.
MLPA Analytical sensitivity >99.99%; Analytical specificity 99.99%.
Clinical sensitivity (proportion of positive tests if the disease is present) and clinical specificity (proportion of negative tests if the disease is not present)
Clinical sensitivity is estimated at about 25% (2).
Clinical specificity: data not available.
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for LMs; b) the sensitivity of the test is greater than or equal to that of tests described in the literature.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis Yes
Differential diagnosis Yes
Couple risk assessment Yes
Availability of clinical trials can be checked on-line at https://clinicaltrials.gov/
